Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price was down 4% during mid-day trading on Thursday . The stock traded as low as $6.02 and last traded at $6.02. Approximately 1,125 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 42,329 shares. The stock had previously closed at $6.27.
Analyst Ratings Changes
VALN has been the topic of a number of recent research reports. Guggenheim lowered their price objective on Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Valneva in a research note on Tuesday, April 15th.
Get Our Latest Report on VALN
Valneva Stock Down 1.9%
The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a market capitalization of $514.36 million, a P/E ratio of -47.31 and a beta of 1.81. The stock has a 50 day moving average price of $6.46 and a 200-day moving average price of $5.92.
Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.27. The business had revenue of $51.79 million during the quarter, compared to analyst estimates of $41.80 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, research analysts expect that Valneva SE will post 0.13 EPS for the current fiscal year.
Institutional Trading of Valneva
Institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its holdings in Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after buying an additional 30,859 shares in the last quarter. ABC Arbitrage SA acquired a new position in shares of Valneva during the 4th quarter worth approximately $84,000. Finally, GAMMA Investing LLC acquired a new position in shares of Valneva during the 1st quarter worth approximately $94,000. Hedge funds and other institutional investors own 11.39% of the company's stock.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
